Inhibition of the Intrinsic but Not the Extrinsic Apoptosis Pathway Accelerates and Drives Myc-Driven Tumorigenesis Towards Acute Myeloid Leukemia
Authors:
Open Access
- 29 February 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (2) , e31366
Abstract
Myc plays an important role in tumor development, including acute myeloid leukemia (AML). However, MYC is also a powerful inducer of apoptosis, which is one of the major failsafe programs to prevent cancer development. To clarify the relative importance of the extrinsic (death receptor-mediated) versus the intrinsic (mitochondrial) pathway of apoptosis in MYC-driven AML, we coexpressed MYC together with anti-apoptotic proteins of relevance for AML; BCL-XL/BCL-2 (inhibiting the intrinsic pathway) or FLIPL (inhibiting the extrinsic pathway), in hematopoietic stems cells (HSCs). Transplantation of HSCs expressing MYC into syngeneic recipient mice resulted in development of AML and T-cell lymphomas within 7–9 weeks as expected. Importantly, coexpression of MYC together with BCL-XL/BCL-2 resulted in strongly accelerated kinetics and favored tumor development towards aggressive AML. In contrast, coexpression of MYC and FLIPL did neither accelerate tumorigenesis nor change the ratio of AML versus T-cell lymphoma. However, a change in distribution of immature CD4+CD8+ versus mature CD4+ T-cell lymphoma was observed in MYC/FLIPL mice, possibly as a result of increased survival of the CD4+ population, but this did not significantly affect the outcome of the disease. In conclusion, our findings provide direct evidence that BCL-XL and BCL-2 but not FLIPL acts in synergy with MYC to drive AML development.Keywords
This publication has 51 references indexed in Scilit:
- Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemiaJournal of Experimental Medicine, 2010
- MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL familyOncogene, 2009
- Reflecting on 25 years with MYCNature Reviews Cancer, 2008
- TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesisJournal of Clinical Investigation, 2008
- c‐Myc primed mitochondria determine cellular sensitivity to TRAIL‐induced apoptosisThe EMBO Journal, 2007
- MYC levels govern hematopoietic tumor type and latency in transgenic miceBlood, 2006
- Evasion of the p53 tumour surveillance network by tumour-derived MYC mutantsNature, 2005
- Direct Repression of FLIP Expression by c-myc Is a Major Determinant of TRAIL SensitivityMolecular and Cellular Biology, 2004
- Apoptosis Triggered by Myc-Induced Suppression of Bcl-XL or Bcl-2 Is Bypassed during LymphomagenesisMolecular and Cellular Biology, 2001
- The treatment of acute non-lymphocytic leukemiaBlood Reviews, 1987